sorafenib has been researched along with mocetinostat in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (mocetinostat) | Trials (mocetinostat) | Recent Studies (post-2010) (mocetinostat) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 21,735 | 390 | 8,606 |
| Protein | Taxonomy | sorafenib (IC50) | mocetinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.7851 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.022 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.57 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.102 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.102 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.3433 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3537 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.6386 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.6725 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Liu, X; Meng, X; Qi, X; Xu, K; Zhu, X | 1 |
2 other study(ies) available for sorafenib and mocetinostat
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Endocytosis; Ferroptosis; Hep G2 Cells; Humans; Iron; Lipid Peroxidation; Liver Neoplasms; Metal-Organic Frameworks; Mice; Nanoparticles; Oligopeptides; Peroxidase; Rabbits; Sorafenib; Toxicity Tests | 2021 |